Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02008851
Other study ID # TNG-CL011
Secondary ID
Status Terminated
Phase Phase 1
First received December 6, 2013
Last updated December 10, 2014
Start date December 2013
Est. completion date December 2014

Study information

Verified date December 2014
Source Tengion
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if selected renal cells, obtained by biopsy from a patient with chronic kidney disease (CKD) and Type 2 Diabetes (i.e., autologous cells) can be safely implanted back into the patient.


Description:

This is a Phase 1 safety and tolerability study to determine if NKA, manufactured from a patient's renal biopsy tissue, can be safely implanted back into the kidney of the patient. Patients must have CKD and Type 2 Diabetes.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date December 2014
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender Both
Age group 30 Years to 70 Years
Eligibility Inclusion Criteria:

- Patients with type 2 diabetes mellitus (T2DM).

- Patients with CKD defined as glomerular filtration rate (GFR) of 20 - 50 mL/min/1.73m2, inclusive.

- Microalbuminuria that cannot be explained by an alternative diagnosis. Microalbuminuria is defined as a urinary albumin-creatinine ration (UACR) = 30 mg/g or urine albumin excretion = 30 mg/day on 24 hour urine collection.

- Ongoing treatment with ACEi or ARB. Patients who are intolerant may be included as long as they have stable blood pressure.

- Systolic blood pressure between 105 and 140 mmHg (inclusive) and diastolic blood pressure = 90 mmHg.

- The patient should have historical data to provide a reasonable estimate of the rate of progression of CKD

Exclusion Criteria:

- Type 1 diabetes mellitus (DM).

- History of a renal transplant.

- HbA1c > 10% at Screening.

- Hemoglobin levels < 9 g/dL prior to biopsy or implant.

- Known allergy to kanamycin or structurally similar aminoglycoside antibiotics.

- Abnormal coagulation status as measured by activated partial prothrombin time, international normalized ratio (INR), and/or platelet count.

- Ineligible for a biopsy (e.g., based on size or cortical depth), MRI or renal scintigraphy study (e.g. due to hypersensitivity or allergy) according to standard site practices.

- Not a good candidate for laparoscopic surgical procedure (based on the assessment of the surgeon who will be performing the implant), including patients who are morbidly obese, have excessive fat surrounding the kidney, have a BMI > 45, or who are otherwise at excessive risk for serious complications.

- Clinically significant infection requiring parenteral antibiotics within 6 weeks of biopsy or implantation.

- Patients with small kidneys (average size < 9 cm) or only one kidney. Patients with a rapid decline in renal function over the last 3 months prior to biopsy or acute kidney injury.

- Patients with any of the following conditions prior to biopsy: renal tumors, polycystic kidney disease, renal cysts or other anatomic abnormalities that would interfere with the biopsy or implantation procedure (e.g., cysts in the pathway of the injection for implantation), hydronephrosis, skin infection over proposed biopsy sites, or evidence of a urinary tract infection.

- Female subjects who are pregnant, lactating (breast feeding) or planning a pregnancy during the course of the study.

- History of cancer within the past 3 years (excluding non-melanoma skin cancer and carcinoma in situ of the cervix).

- Life expectancy of less than 2 years.

- Any contraindication or known anaphylactic or severe systemic reaction to either human blood products or materials of animal (bovine, porcine) origin or anesthetic agents.

- Positive for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) assessed.

- Subjects with active tuberculosis (TB) requiring treatment in the past 3 years.

- Immunocompromised subjects or patients receiving immunosuppressive agents.

- Subjects with uncontrolled diabetes, incapacitating cardiac and/or pulmonary disorders.

- History of active alcohol and/or drug abuse that in the investigator's assessment would impair the subject's ability to comply with the protocol.

- Patients with clinically significant hepatic disease.

- Patients with bleeding disorders that would, in the opinion of the Investigator, interfere with the performance of study procedures; patients taking Coumarins (e.g.,Warfarin) or other anticoagulants (e.g. enoxaparin or direct thrombin inhibitors).

- Use of any investigational product within 3 months of the biopsy .

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label


Intervention

Biological:
Neo-kidney augment
Injection of 3.0 x 10e6 selected renal cells into the left kidney of the patient

Locations

Country Name City State
United States Brigham & Women's Hospital Boston Massachusetts
United States UNC Medical Center Chapel Hill North Carolina
United States University of Chicago Medicine Chicago Illinois
United States Vanderbilt University Nashville Tennessee
United States LSU Health Care Services New Orleans Louisiana

Sponsors (1)

Lead Sponsor Collaborator
Tengion

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Changes in renal function over time Exploratory objectives include assessment of renal function over time; e.g., glomerular filtration rate (GFR), serum creatinine, and proteinuria. 12 months No
Primary Number of adverse events related to study procedures or investigational product 12 months No
Secondary Number of renal-specific adverse events 12 months No
See also
  Status Clinical Trial Phase
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Terminated NCT04043026 - The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
Completed NCT05318014 - Low-protein Formula Supplements in Chronic Kidney Disease N/A
Active, not recruiting NCT06071065 - Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients N/A
Completed NCT02878317 - Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
Not yet recruiting NCT06039254 - Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function Phase 1
Recruiting NCT03160326 - The QUALITY Vets Project: Muscle Quality and Kidney Disease
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Withdrawn NCT02885545 - The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial Phase 4
Completed NCT02836574 - A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease Phase 2
Completed NCT02756520 - Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
Completed NCT02875886 - DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease Phase 4
Completed NCT02896309 - The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity N/A
Active, not recruiting NCT02483039 - Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization N/A
Terminated NCT02543177 - Optimised Procedure in Patients With NSTEMI and CKD N/A
Completed NCT02992548 - Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease Phase 4
Completed NCT02369549 - Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease Phase 3
Recruiting NCT02205944 - Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes N/A
Active, not recruiting NCT02231138 - Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Phase 4